

PRESS RELEASE – FOR IMMEDIATE DIFFUSION

18% growth in revenues in H1 2013

EVRY, MONDAY JULY 8TH 2013 - IntegraGen, a leading player in the development and marketing of molecular diagnostic testing in oncology and autism, announced today its revenue for the first half of 2013.

18% growth in Genomic services revenues

IntegraGen SA revenues reached €2,7M as of June 30th, 2013, a growth of 18% compared to 2012. This increase reflects the strong demand for sequencing services and highlights the high quality of performances of the laboratory which provides end-to-end genomic services from DNA or RNA extraction to bio-informatics data management.

ARISK® sales take off in the USA

ARISK®, the first test able to identify the risk of autism in children was launched in 2012. Over the first 6 Months of 2013, IntegraGen experienced a significant increase in demand from physicians willing to prescribe the test. The first version of the test, which targets siblings of an affected child, has already allowed the Company to realize a revenue of \$30K. IntegraGen is now finalizing the development of a new version of the test targeting children with suspicion of autism without any family history. The Company confirms its objective of a commercial launch before the end of 2013

Promising results in Oncology

IntegraGen continues its efforts regarding the development of a diagnostic test for metastatic colorectal cancer, in order to achieve commercial launch in 2014. Furthermore the Company has recently announced the publication of results regarding a prognostic molecular signature in hepatocellular carcinoma (liver cancer) in partnership with the French League against Cancer and INSERM. These results are particularly encouraging in that it could represent a major breakthrough in the management of patients with liver cancer.

Bernard Courtieu, Chief Executive Officer of IntegraGen, declared « *The continued growth of our genomic activities as well as the first revenues issued from our molecular diagnostic tests comfort us in our strategic positioning and allow us to confirm our ambitions for further growth and development for 2013* ».

IntegraGen will publish its H1 results in October 2013.

ABOUT INTEGRAGEN

IntegraGen develops and markets molecular diagnostic tests in the fields of autism and oncology. Wholly subscribing to the universe of personalized medicine, IntegraGen's is dedicated to providing clinicians with personalized diagnostic tools enabling the identification and qualification of anomalies and dysfunctions in the organism in order to prescribe "the right treatment for the right patient".

IntegraGen uses its recognized industry knowledge to support its Genomic Services Business division possessing the first private genomic platform in France. The commercialization of genome decoding services to the most prestigious academic and pharmaceutical entities has allowed IntegraGen to generate revenues of 4.8M€ at the end of 2012.

As of December 31, 2012, IntegraGen had 31 employees. Its headquarters are located at Génopole d'Evry. The Company also has offices in the United States through its affiliate IntegraGen Inc., based in Cambridge, MA. IntegraGen is listed on the Alternext of the NYSE Euronext in Paris (Isin : FR0010908723 - Mnémo : ALINT).

More information is available on the website: www.integragen.com

CONTACTS



INTEGRAGEN

Bernard Courtieu
President, Managing Director
Tel.: +33 (0)1 60 91 09 00

Laurence Riot Lamotte
CFO
contact@integragen.com
Tel.: +33 (0)1 60 91 09 09

NEWCAP.

Investor and Media Relations

Louis-Victor Delouvrier /
Emmanuel Huynh
integragen@newcap.fr
Tel.: +33 (0)1 44 71 94 93